Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some

AACR 2015

18 - 22 Apr 2015

Published: 27 Apr 2015

Views: 2662

Rating:

Save

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Prof Emens presents the results of a phase I trial looking at the use of investigational PD-L1–targeted immunotherapy in the treatment of triple-negative breast cancer during a press conference at AACR 2015.

See the news story for more.

Related Videos

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

ESMO 2024: Latest updates in mRCC

Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane...

ESMO 2024: Latest updates in mRCC ( Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane Oudard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Updates on triple-negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA

Updates on triple-negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA )

More from ecancer